Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Follow-Up Questions
Quelle est la performance du prix de l'action BBLG ?
Le prix actuel de BBLG est de $2.49, il a increased de 0.62% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Bone Biologics Corp ?
Bone Biologics Corp appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Bone Biologics Corp ?
La capitalisation boursière actuelle de Bone Biologics Corp est de $4.4M
Est-ce que Bone Biologics Corp est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Bone Biologics Corp, y compris 2 achat fort, 4 achat, 1 maintien, 0 vente et 2 vente forte